Stifel Initiates Coverage On MapLight Therapeutics with Buy Rating, Announces Price Target of $28

MapLight Therapeutics, Inc. +0.82%

MapLight Therapeutics, Inc.

MPLT

18.49

+0.82%

Stifel analyst Paul Matteis initiates coverage on MapLight Therapeutics (NASDAQ: MPLT) with a Buy rating and announces Price Target of $28.
Every question you ask will be answered
Scan the QR code to contact us
whatsapp
Also you can contact us via